Literature DB >> 26637923

Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.

Ken Shirabe1, Keishi Sugimachi2, Noboru Harada3, Hiroto Kayashima3, Takashi Maeda3, Eiji Tsujita3, Ryosuke Minagawa4, Kiyoshi Kajiyama4, Shohei Yoshiya4, Yoshihiko Maehara5.   

Abstract

BACKGROUND: A sustained virological response (SVR) to interferon (IFN) therapy for chronic hepatitis C virus (HCV) reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). The prognosis after hepatectomy for HCC in patients with SVR has not been fully clarified. PATIENTS AND METHODS: Between 1998 and 2011, 494 patients with chronic hepatitis C underwent hepatic resection for HCC at four high-volume Centers in Japan. Out of these, 188 underwent IFN therapy for HCV. In 92 patients, SVR to IFN therapy had been achieved at the time of hepatectomy (SVR group) while in 96 patients, SVR had not (non-SVR group) had not been achieved. In the other 306 patients, IFN therapy had never been performed at all (no IFN group). The clinicopathological factors and long-term outcomes were retrospectively reviewed and compared among SVR, non-SVR and no IFN groups.
RESULTS: The mean time from achievement of SVR to hepatectomy for HCC was 6.2 years (range=2 months to 20 years). The preoperative serum alanine transaminase, albumin, prothrombin time, indocyanine green retention test at 15 min were significantly preserved in the SVR group. The overall survival and recurrence-free survival rates were significantly higher in the SVR group compared to patients in non-SVR and no IFN groups.
CONCLUSION: In patients undergoing hepatectomy for HCC, those with SVR had good liver function and a more favorable long-term prognosis than those without SVR. Early detection of HCC after SVR and meticulous hepatectomy with small blood loss is important in patients with HCC after hepatectomy. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Chronic hepatitis C; hepatectomy; hepatocellular carcinoma; interferon; sustained virological response

Mesh:

Substances:

Year:  2015        PMID: 26637923

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?

Authors:  Masahiro Ogawa; Tatsuo Kanda; Mitsuhiko Moriyama
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

2.  Viral elimination is essential for improving surgical outcomes of hepatitis C virus-related hepatocellular carcinoma: Multicenter retrospective analysis.

Authors:  Masao Nakajima; Shogo Kobayashi; Hiroshi Wada; Akira Tomokuni; Hidenori Takahashi; Takehiro Noda; Hiroto Matsui; Satoshi Matsukuma; Shinsuke Kanekiyo; Yoshitaro Shindo; Yukio Tokumitsu; Yuki Nakagami; Nobuaki Suzuki; Shigeru Takeda; Masahiro Tanabe; Katsuyoshi Ito; Yoshinobu Hoshii; Hidetoshi Eguchi; Hiroaki Nagano
Journal:  Ann Gastroenterol Surg       Date:  2020-07-23

3.  Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term.

Authors:  Mahmoud Atamla; Johad Khoury; Ihab Dabbah; Rimma Kramsky; Afif Yaacob; Ella Veitsman; Tarek Saadi
Journal:  Clin Exp Hepatol       Date:  2021-09-20

4.  Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma.

Authors:  Byung Soo Kwan; Jeong Han Kim; Seong Jun Park; Won Hyeok Choe; So Young Kwon; Byung-Chul Yoo
Journal:  Korean J Intern Med       Date:  2020-04-03       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.